Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,586 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial).
Orditura M, Gravina A, Riccardi F, Diana A, Mocerino C, Leopaldi L, Fabozzi A, Giordano G, Nettuno R, Incoronato P, Barzelloni ML, Caputo R, Pisano A, Grimaldi G, Genua G, Montesarchio V, Barbato E, Iodice G, Lieto E, Procaccini E, Mabilia R, Febbraro A, Laurentiis M, Ciardiello F. Orditura M, et al. Among authors: giordano g. ESMO Open. 2017 Jun 2;2(2):e000176. doi: 10.1136/esmoopen-2017-000176. eCollection 2017. ESMO Open. 2017. PMID: 28761747 Free PMC article.
Metastatic melanoma: an unusual presentation.
De Vita F, Giordano G, Fabozzi A, Guerrera B, Fabozzi T, Fasano M, Ferrara M, Fascione A, Di Benedetto G. De Vita F, et al. Among authors: giordano g. Tumori. 2011 Jan-Feb;97(1):130-2. doi: 10.1177/030089161109700124. Tumori. 2011. PMID: 21528678
Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer.
Giordano G, Febbraro A, Tomaselli E, Sarnicola ML, Parcesepe P, Parente D, Forte N, Fabozzi A, Remo A, Bonetti A, Manfrin E, Ghasemi S, Ceccarelli M, Cerulo L, Bazzoni F, Pancione M. Giordano G, et al. J Exp Clin Cancer Res. 2015 Oct 1;34:108. doi: 10.1186/s13046-015-0225-7. J Exp Clin Cancer Res. 2015. PMID: 26427914 Free PMC article.
Cancer drug related cardiotoxicity during breast cancer treatment.
Giordano G, Spagnuolo A, Olivieri N, Corbo C, Campagna A, Spagnoletti I, Pennacchio RM, Campidoglio S, Pancione M, Palladino L, Villari B, Febbraro A. Giordano G, et al. Expert Opin Drug Saf. 2016 Aug;15(8):1063-74. doi: 10.1080/14740338.2016.1182493. Epub 2016 Jul 6. Expert Opin Drug Saf. 2016. PMID: 27120499 Review.
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.
Ciccarese M, Fabi A, Moscetti L, Cazzaniga ME, Petrucelli L, Forcignanò R, Lupo LI, De Matteis E, Chiuri VE, Cairo G, Febbraro A, Giordano G, Giampaglia M, Bilancia D, La Verde N, Maiello E, Morritti M, Giotta F, Lorusso V, Latorre A, Scavelli C, Romito S, Cusmai A, Palmiotti G, Surico G. Ciccarese M, et al. Among authors: giordano g. Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28. Breast Cancer Res Treat. 2017. PMID: 28353061
1,586 results